Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Iterum Therapeutics plc
ITRM
Healthcare
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in...
Phase III clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ITRM)
New Post
View:
Posts & Comments
Threaded Posts
(7)
•••
Ltcguy2001
X
Comment by
Ltcguy2001
on Oct 28, 2024 8:02pm
RE:Iterum Therapeutics to Host Morning Conference Call on U.S.
I was lucky to take a small 5,000 share position last Thursday @$1.20 and sold Friday at $2.18. Took my $6k back off the table but bought 3,500 @$1.40 with left over. Free and clear long
...more
(268)
•••
whytestocks
X
Post by
whytestocks
on Oct 28, 2024 5:32am
Iterum Therapeutics to Host Morning Conference Call on U.S.
Just In: $ITRM Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH(TM) (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsIterum Therapeutics
...more
Access North American AND Australian listed and Pre-IPO opportunities – here!
posted Dec 02, 2024 9:00am by
Stockhouse Publishing Ltd.
-
|
For the first time on Stockhouse, Canadian investors can access ASX-listed opportunities through our partnership with HotCopper in Australia, opening doors to high-potential investments at the click of a button. Learn more here… ...read more
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 2:09am
Iterum Therapeutics plc: Resubmitted NDA for Oral Sulopenem
https://beyondspx.com/2024/08/02/iterum-therapeutics-plc-resubmitted-nda-for-oral-sulopenem-positions-company-for-potential-approval-in-q4-2024/
(268)
•••
whytestocks
X
Post by
whytestocks
on Jun 05, 2024 10:00pm
Iterum Therapeutics to Present Data at ASM Microbe 2024
BREAKING NEWS: $ITRM Iterum Therapeutics to Present Data at ASM Microbe 2024DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Jan 11, 2023 6:00pm
New Press Release - Iterum Therapeutics Reports Employment Inducement Grant
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 15, 2022 3:05pm
ITRM ..... I'll take that profit ; )
Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 15, 2022 2:13pm
ITRM.... from hero to chump to......
Hero? Maybe...... Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 15, 2022 2:09pm
ITRM.....well well well
needs some volume
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 15, 2022 1:58pm
ITRM .... if and thats a big if ; )
This can bust thru $1.25 with some vols....I will entertain the idea to take a position
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 15, 2022 12:30pm
ITRM ...... What a deal ; )
LoL.....1 big P & D Now at L.O.D $1.17 What now ?
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 15, 2022 9:43am
ITRM...In watch
On watch
(22)
•••
wallpaper2
X
Post by
wallpaper2
on Jun 27, 2021 10:18am
Telling after close purchase on Iterum.
Someone purchased 25000 shares at S2.23 at the close. Six million shares crossed earlier. Something very good happening? Three weeks of trading before FDA approval and multiple move in share price
...more
(22)
•••
wallpaper2
X
Post by
wallpaper2
on Jun 22, 2021 10:46am
We're very close folks.
FDA decision July 24th and a lot of buying has taken place this month! FDA were satisfied with everything after their last get together. Rubber meets the road soon.
(22)
•••
wallpaper2
X
Comment by
wallpaper2
on Jun 14, 2021 12:42pm
RE:ITRM on verge of breakout on expected FDA approval ??
It wants to run but they are smart and backfilling first.
(22)
•••
wallpaper2
X
Post by
wallpaper2
on Jun 12, 2021 1:29pm
ITRM on verge of breakout on expected FDA approval ??
You tell me.... volume and sp both moving higher which is very bullish. Are people in the know cheating and getting in early on anticipation. Was the recent meeting with the FDA a big positive. WC
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
Debt-Free Cannabis Company Set for Next Stage of Growth